Jesse Bloom
As seen in:
MSN,
The New York Times,
The New York Times en Español,
Nature,
CNET,
PLOS Biology,
MDPI,
The Conversation,
Channel 4 News,
Observer
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jesse Bloom
RSM01, an extended half-life RSV monoclonal antibody with a high barrier to in vitro resistance
Abstract Respiratory syncytial virus (RSV) causes substantial infant morbidity and mortality, particularly in low- and middle-income countries (LMICs). RSM01 is a long-acting RSV monoclonal antibody (mAb) in development for LMICs. In vitro generation of RSM01 resistant mutants has previously been unsuccessful. We systematically assessed the in vitro resistance barrier of RSM01 and the susceptibility of a panel of global contemporary strains to RSM01.
The SARS-CoV-2 spike receptor-binding domain has evolved decreased inherent antigenicity in humans
JDB consults for Apriori Bio, GSK, Pfizer, and Merck. JDB is an inventor on Fred Hutch licensed patents related to deep mutational scanning of viral proteins. JBB receives research funding from Third Rock Ventures, Frazier Life Sciences, and AstraZeneca.
An mRNA–lipid nanoparticle vaccine against H5N1 influenza virus protects lactating dairy cows from infection
|
Abstract Highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5N1 virus has recently emerged in dairy cattle in the USA, leading to mastitis and sharp reductions in milk production. The main site of H5N1 viral replication is the mammary tissue rather than the respiratory tract and viral transmission between animals is thought to occur through viral shedding in milk.
By Jefferson Santos, Carine K. Souza, Giovana C. Zanella, Debora Goulart, Bailey Arruda, Paola M. Boggiatto, Mitchell V. Palmer, Celeste A. Snyder, Terry Webb, Reilly K. Atkinson, Bernadeta Dadonaite, Garima Dwivedi, Mohamad-Gabriel Alameh, Christopher Hunter, Lisa Murphy, Jesse Bloom, Drew Weissman, Gary C. Althouse, Amy Baker, Scott Hensley Verified, Michaela A. Kristula, Charlene Dickens
|
Nature
Verified
Coevolutionary constraints of Zika virus nonstructural protein 5 replication and interferon antagonism activities
Abstract The flavivirus nonstructural protein 5 performs multiple functions during infection, including RNA replication and type I interferon signaling antagonism. Although flavivirus NS5 proteins inhibit IFN signaling through distinct mechanisms, which suggests evolutionary flexibility, the evolutionary constraints for these activities to coexist within a single protein remain to be determined.
Mutational constraints on RSV F and its neutralization by antibodies
Abstract New antibodies targeting the F protein of respiratory syncytial virus (RSV) have substantially reduced infant hospitalizations1. However, viral resistance is a concern: one antibody failed clinical trials because of a resistant strain2, and sporadic resistance mutations to the most widely used antibody (nirsevimab) have been identified3,4,5,6. Here we define how RSV F mutations affect antibody neutralization.
Potent type-specific de novo antibodies complement broadly reactive imprinted antibodies in immune responses to SARS-CoV-2 variants
|
Abstract For rapidly mutating viruses such as influenza viruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), immune memory recalled by antigenically drifted variants primarily comprises antibodies that cross-react to the priming strain rather than de novo elicited responses, a phenomenon termed original antigenic sin or immune imprinting. The composition and functionality of de novo responses elicited by variant exposures remain unclear.
By Timothy Johnston, Shuk Hang Li, Mark Painter, Divya Swaminathan, Reilly K. Atkinson, Bernadeta Dadonaite, Shuishu Wang, Naomi R. Douek, Lucas Kampman, Rachel Kazmierski, Bob Lin, Leonid Serebryannyy, Haijuan Du, Amy Henry, Sarah Smith, Farida Laboune, I-Ting Teng, Lingshu Wang, Nicole A. Doria-Rose, Chaim A. Schramm, Theodore C. Pierson, Tongqing Zhou, Jesse Bloom, E. John Wherry, Scott Hensley Verified, Daniel Douek, Robin Schlesinger
|
Nature
Verified
mRNA-based influenza vaccine expands the B cell response breadth in humans
|
Abstract Conventional influenza virus vaccines induce antibody responses of limited breadth. Whether mRNA-based influenza virus vaccines can induce a superior germinal center (GC) response in humans remains unclear. Here we assessed B cell responses in an observational study of cohorts of healthy young adults receiving a licensed, split-virion or investigative mRNA-based quadrivalent seasonal influenza virus vaccine over two consecutive seasons.
By Hanover C. Matz, Tae-Geun Yu, Kritika Dixit, Caroline Kikawa, Julian Q. Zhou, Garazi Pena Alzua, Lowrey Peyton, Anders K. Madsen, Fangjie Han, Ariana Ghez Farrell, Robert Hoelzl, Aaron J. Schmitz, Stephen Horvath, Hunter K Keplinger, Benjamin S. Strnad, Mark J. Hoegger, William Middleton, Michael K. Klebert, Nina Lin, Raffael Nachbagauer, Florian Krammer, Robert M. Paris, Jesse Bloom, Jackson Turner, Rachel M. Presti, Jiwon Lee, Ali H Ellebedy
|
Nature
Verified
A cocktail of human mAbs targeting the henipavirus fusion and receptor binding proteins provides cross-species neutralization
|
Editor’s summary Abstract Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations Check Access References Figures Tables Media Share Editor’s summary Hendra virus (HeV) and Nipah virus (NiV) are zoonotic pathogens with high mortality rates in humans and other mammals. There are currently no approved human vaccines or therapeutics for those infected with these deadly pathogens. Here, Guzmán-Solís et al.
By Kyeongseok Jeon, Axel A Guzmán-Solís, Rory Malek, Mohamed Ouizougun-Oubari, Olivier Escaffre, Brendan B Larsen, Mary Lopez, Madhu S. Kumar, Terry Juelich, Jennifer Smith, Lihong Zhang, Griffin Haas Verified, Luca Brambilla, Kasopefoluwa Oguntuyo, Iden Sapse, Thomas A. Bowden, Domenico Tortorella, Jesse Bloom, Alexander N. Freiberg, Goran Bajic, James Duty, Benhur Lee, Selina Locklear, Rachel Roenicke
|
Science Magazine
Verified
Replaying germinal center evolution on a quantified affinity landscape
|
GCs select consistently for increases in affinity and maintenance of Ig expression Whereas GC phylogenies varied widely in structure (Figures 1C, 1D, and S2), replay GCs were much more consistent with respect to affinity maturation. Median affinity was higher than naive in 117 of 119 GCs, whereas variance was relatively low (0.87 ± 0.38 at 15 dpi and 1.00 ± 0.34 at 20 dpi [mean ± SD]; Figures 4A and S5A).
By William DeWitt, Ashni A. Vora, Tatsuya Araki, Jared Galloway, Tanwee Alkutkar, Juliana Bortolatto, Tiago Castro, Will Dumm, Chris Jennings-Shaffer, Tongqiu Jia, Luka Mesin, Gabriel Ozorowski, Juhee Pae, Duncan Ralph, Jesse Bloom, Armita Nourmohammad, Yun S. Song, Andrew Ward, Tyler Starr, Frederick A. Matsen, Gabriel D. Victora
|
Cell Press
Verified
Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope - Nature Immunology
Abstract Broadly neutralizing antibodies (bNAbs) against HIV-1 can suppress viremia in vivo and inform vaccine development. Here we characterized 007, a V3 glycan site bNAb exhibiting high levels of antiviral activity against multiclade pseudovirus panels. 007 targets an N332gp120 glycan-independent V3 epitope, a site of the HIV-1 envelope protein (Env) vulnerability to which only weakly neutralizing antibodies had previously been identified.
Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses - Nature Microbiology
Abstract Highly pathogenic avian influenza H5Nx viruses are an emerging threat for global health, especially clade 2.3.4.4b H5N1 virus which causes panzootic infections. Here we describe the isolation and characterization of broadly cross-neutralizing monoclonal antibodies (mAbs) against diverse H5Nx viruses from individuals who received a monovalent H5N1 vaccine 15 years ago.
Combined crystallographic fragment screening and deep mutational scanning enable discovery of Zika virus NS2B-NS3 protease inhibitors - Nature Communications
Abstract The Zika viral protease NS2B-NS3 is essential for the cleavage of viral polyprotein precursor into individual structural and non-structural (NS) proteins and is therefore an attractive drug target. Generation of a robust crystal system of co-expressed NS2B-NS3 protease has enabled us to perform a crystallographic fragment screening campaign with 1076 fragments.
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy - Nature Immunology
Abstract Administration of HIV-1 neutralizing antibodies can suppress viremia and prevent infection in vivo. However, clinical use is challenged by envelope diversity and rapid viral escape. Here, we performed single B cell profiling of 32 top HIV-1 elite neutralizers to identify broadly neutralizing antibodies with highest antiviral activity.
Loss of FCoV-23 spike domain 0 enhances fusogenicity and entry kinetics - Nature
Abstract The ability of coronaviruses to recombine and cross species barriers affects human and animal health globally and is a pandemic threat1,2. FCoV-23 is a recently emerged, highly pathogenic recombinant coronavirus responsible for a widespread outbreak of feline infectious peritonitis. Here we report cryogenic electron microscopy structures of two FCoV-23 spike isoforms that correspond to the in-host loss of domain 0 observed in clinical samples.
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning - Nature Communications
Abstract Antibodies targeting the highly conserved prehairpin intermediate (PHI) of class I viral membrane-fusion proteins are generally weakly neutralizing and are not considered viable therapeutic agents. We previously demonstrated that antibodies targeting the gp41 N-heptad repeat (NHR), which is transiently exposed in the HIV-1 PHI, exhibit enhanced broad neutralization in cells expressing the Fc receptor, FcγRI.
Functional and antigenic landscape of the Nipah virus receptor-binding protein
ArticleOnline nowOpen access 1Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA 2Department of Biochemistry, University of Washington, Seattle, WA 98195, USA 3Department of Pathology Microbiology and Immunology, The Vanderbilt Vaccine Center, and Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA 4Howard Hughes Medical Institute, Seattle, WA 98195, USA Publication History: Received May 8,...
Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains
Abstract Antibodies capable of neutralizing many strains of HIV are being explored as prophylactic and therapeutic agents, but viral escape mutations pose a major challenge. Efforts have been made to experimentally define the escape mutations from specific antibodies in specific viral strains, but it remains unclear how much the effects of mutations on neutralization differ among HIV strains.
embo-workshop
Fred Hutch Cancer Center / HHMI These slides athttps://slides.com/jbloom/embo-workshop New variants (mutants) are always arising during viral evolution Can we predict evolutionary success of viral variants from the biochemical effects of their constituent mutations?
Computationally restoring the potency of a clinical antibody against Omicron - Nature
Abstract The COVID-19 pandemic underscored the promise of monoclonal antibody-based prophylactic and therapeutic drugs1,2,3 and revealed how quickly viral escape can curtail effective options4,5. When the SARS-CoV-2 Omicron variant emerged in 2021, many antibody drug products lost potency, including Evusheld and its constituent, cilgavimab4,5,6.
Dynamics and durability of HIV-1 neutralization are determined by viral replication - Nature Medicine
Abstract Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers—persons with HIV-1 who naturally develop broad and potent nAbs—can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens.
dms-viz: Structure-informed visualizations for deep mutational scanning and other mutation-based datasets
Abstract Understanding how mutations impact a protein's functions is valuable for many types of biological questions. High-throughput techniques such as deep-mutational scanning (DMS) have greatly expanded the number of mutation-function datasets. For instance, DMS has been used to determine how mutations to viral proteins affect antibody escape, receptor affinity, and essential functions such as viral genome transcription and replication.
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
Highlights • Isolated bnAbs 12-16 and 12-19 from a SARS-CoV-2 recovered/vaccinated individual • These mAbs target a conserved quaternary epitope at the interface between NTD-SD1 • The mAbs neutralize all current SARS-CoV-2 VOCs by locking RBD in down conformation • 12-19 escape mutations are rarely found in circulating SARS-CoV-2 viruses Summary SARS-CoV-2 continues to evolve, with many variants evading clinically authorized antibodies.
new_2nd_gen_BA2_variant
New BA.2.86 variant has many spike amino-acid mutations relative to its BA.2 parent, and is an evolutionary jump similar in size to that which originally gave rise to Omicron. Many of these mutations are antigenically important, indicating BA.2.86 variant evolved under strong antibody selection. Deep mutational scanning indicates BA.2.86 variant will have equal or greater escape than XBB.1.5 from antibodies elicited by pre-Omicron and first-generation Omicron variants.
Jointly modeling deep mutational scans identifies shifted mutational effects among SARS-CoV-2 spike homologs
New Results doi: https://doi.org/10.1101/2023.07.31.551037 Abstract Deep mutational scanning (DMS) is a high-throughput experimental technique that measures the effects of thousands of mutations to a protein. These experiments can be performed on multiple homologs of a protein or on the same protein selected under multiple conditions. It is often of biological interest to identify mutations with shifted effects across homologs or conditions.
Fitness effects of mutations to SARS-CoV-2 proteins
New Results doi: https://doi.org/10.1101/2023.01.30.526314 ABSTRACT Knowledge of the fitness effects of mutations to SARS-CoV-2 can inform assessment of new variants, design of therapeutics resistant to escape, and understanding of the functions of viral proteins. However, experimentally measuring effects of mutations is challenging: we lack tractable lab assays for many SARS-CoV-2 proteins, and comprehensive deep mutational scanning has been applied to only two SARS-CoV-2 proteins.
Evolution of antibody immunity following Omicron BA.1 breakthrough infection - Nature Communications
Human subjects and blood sample collection Seven BA.1 breakthrough-infected participants were recruited to participate in this study with informed consent under the Dartmouth Health Protocol D10083, approved by the Dartmouth Health Human Research Protection Program Institutional Review Board, and overseen by DartLab, a Dartmouth Cancer Center Shared Resource. Participants were compensated $3 for every 10 ml of blood given.
huanan-market-samples
Many samples with the most virus derive their animal genetic material from species that were clearly not infected. No consistent correlation between the SARS-CoV-2 content and genetic material from susceptible species. There are potential confounders that cannot be adequately corrected for, but clearly by time of sampling, the virus was spread widely enough to be co-mingled with material from species that were definitely not infected.
Association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Fitness effects of mutations to SARS-CoV-2 proteins
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Molecular fate-mapping of serum antibody responses to repeat immunization - Nature
Abstract The protective efficacy of serum antibody results from the interplay of antigen-specific B cell clones of different affinities and specificities. These cellular dynamics underlie serum-level phenomena such as “Original Antigenic Sin” (OAS), a proposed propensity of the immune system to rely repeatedly on the first cohort of B cells engaged by an antigenic stimulus when encountering related antigens, in detriment of inducing de novo responses1-5.
Evolution of the SARS-CoV-2 mutational spectrum
New Results doi: https://doi.org/10.1101/2022.11.19.517207 Abstract SARS-CoV-2 evolves rapidly in part because of its high mutation rate. Here we examine whether this mutational process itself has changed during viral evolution. To do this, we quantify the relative rates of different types of single nucleotide mutations at four-fold degenerate sites in the viral genome across millions of human SARS-CoV-2 sequences.
Opinión: Soy virólogo y tengo una petición: hagamos que el estudio de los virus sea más seguro Original
A la humanidad la han invadido virus mucho más devastadores que el coronavirus que causa la COVID-19. La viruela, por ejemplo, llegó a matar al de las personas contagiadas. Gracias a la ciencia, ahora es una plaga del pasado: el último contagio natural se produjo . Sin embargo, los últimos casos de viruela tuvieron su origen en un laboratorio, cuando en 1978 una fotógrafa médica británica se contagió por accidente en la Facultad de Medicina de la Universidad de Birmingham.
Soy virólogo y tengo una petición: hagamos que el estudio de los virus sea más seguro
Ensayo invitado 2 de noviembre de 2022 a las 04:00 ET Credit...Carolina Moscoso Send any friend a story As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share. Por Jesse Bloom Bloom estudia la evolución del virus en el Fred Hutchinson Cancer Center en Seattle. A la humanidad la han invadido virus mucho más devastadores que el coronavirus que causa la COVID-19. La viruela, por ejemplo, llegó a matar al de las personas contagiadas.
A plea for making virus research safer
A plea for making virus research safer, Opinion - THE BUSINESS TIMES
Opinion | A Plea for Making Virus Research Safer
Viruses far more devastating than the coronavirus that causes Covid-19 have plagued humankind. Smallpox, for example, killed up to of people it infected. Thanks to science, it’s now a plague of the past, with the last natural infection occurring. But the last cases of smallpox came from a lab, when a British medical photographer was accidentally infected at the University of Birmingham Medical School in 1978.
sars2-variants-2022-10-17
Jesse Bloom Fred Hutch Cancer Center / HHMI These slides athttps://slides.com/jbloom/sars2-variants-2022-10-17 @jbloom_lab I am on the scientific advisory boards of Apriori Bio and Oncorus I have consulted on topics related to viral evolution for Moderna and Merck I am an inventor on Fred Hutch licensed patents related to deep mutational scanning of viral proteins Conceptual background on human coronavirus evolution Current SARS-CoV-2 variants Conceptual background on human coronavirus...
Creemos que este es el futuro del coronavirus
Por Sarah Cobey, Jesse Bloom, Tyler Starr y Nathaniel Lash Cobey estudia la interacción de la inmunidad con la evolución y transmisión del virus en la Universidad de Chicago. Bloom y Starr estudian la evolución del virus en el Centro de Investigación del Cáncer Fred Hutchinson en Seattle. Lash es editor de gráficos de Opinión. En nuestra calidad de científicos que estudian cómo evolucionan los virus, a menudo se nos pregunta sobre el futuro del coronavirus. ¿Desaparecerá? ¿Irá a peor?
Opinion | We Study Virus Evolution. Here’s Where We Think the Coronavirus Is Going.
By Sarah Cobey, Jesse Bloom and Tyler Starr and Nathaniel Lash Dr. Cobey studies the interaction of immunity, virus evolution and transmission at the University of Chicago. Dr. Bloom and Dr. Starr study virus evolution at Fred Hutchinson Cancer Research Center in Seattle. Mr. Lash is a graphics editor for Opinion. As scientists who study how viruses evolve, we are often asked about the future of the coronavirus. Will it go away? Get worse? Fade into the background of our lives?
shifting-rbd-landscape-niaid-save
The shifting evolutionary landscape of SARS-CoV-2's receptor binding domain Jesse Bloom Fred Hutch Cancer Research Center / HHMI Slides athttps://slides.com/jbloom/shifting-rbd-landscape-niaid-save @jbloom_lab I am on the scientific advisory boards of Flagship Labs 77 and Oncorus I consult for Moderna I am an inventor on Fred Hutch licensed patents related to deep mutational scanning of viral proteins My lab has unfunded research collaborations with Vir Biotechnology Omicron has many...
ACE2 binding is an ancestral and evolvable trait of sarbecoviruses - Nature
Abstract Two different sarbecoviruses have caused major human outbreaks in the last two decades1,2. Both of these sarbecoviruses, SARS-CoV-1 and SARS-CoV-2, engage ACE2 via the spike receptor-binding domain (RBD)2–6. However, binding to ACE2 orthologs from humans, bats, and other species has been observed only sporadically among the broader diversity of bat sarbecoviruses7–11.
sars-cov-2-omicron
Interpreting the evolution of SARS-CoV-2 in context of Omicron Jesse Bloom Fred Hutch Cancer Research Center / HHMI Slides athttps://slides.com/jbloom/sars-cov-2-omicron @jbloom_lab I am on the scientific advisory boards of Flagship Labs 77 and Oncorus I consult for Moderna I am an inventor on Fred Hutch licensed patents related to deep mutational scanning of viral proteins My lab has unfunded research collaborations with Vir Biotechnology Principles of viral antigenic evolution and emergence...
Guía de dos científicos para entender la variante ómicron
Partículas del virus SARS-CoV-2 que causan COVID-19. Credit Azaibi Tamin Hannah A. Bullock/CDC vía Associated Press Durante los próximos días y semanas, científicos de todo el mundo compartirán información preliminar sobre la variante ómicron del SARS-CoV-2. Quienes escribimos este ensayo somos investigadores que estudiamos la evolución de los virus y revisaremos con cuidado los datos conforme se hagan públicos.
Guía de dos científicos para entender la variante ómicron
Durante los próximos días y semanas, científicos de todo el mundo compartirán información preliminar sobre la variante ómicron del SARS-CoV-2. Quienes escribimos este ensayo somos investigadores que estudiamos la evolución de los virus y revisaremos con cuidado los datos conforme se hagan públicos.
Opinion | A Scientist’s Guide to Understanding Omicron
Over the coming days and weeks, scientists from around the world will be sharing early information about the new Omicron variant of SARS-CoV-2. We are two researchers who study the evolution of viruses, and we will be keeping a close eye on the data as it becomes public. This new research will range from laboratory studies investigating how the virus interacts with antibodies to observations of patient outcomes to large-scale data on infections and hospitalizations.
Recovery of deleted deep sequencing data sheds more light on the early Wuhan SARS-CoV-2 epidemic
Abstract The origin and early spread of SARS-CoV-2 remains shrouded in mystery. Here I identify a data set containing SARS-CoV-2 sequences from early in the Wuhan epidemic that has been deleted from the NIH's Sequence Read Archive. I recover the deleted files from the Google Cloud, and reconstruct partial sequences of 13 early epidemic viruses.
Recovery of deleted deep sequencing data sheds more light on the early Wuhan SARS-CoV-2 epidemic
ABSTRACT The origin and early spread of SARS-CoV-2 remains shrouded in mystery. Here I identify a data set containing SARS-CoV-2 sequences from early in the Wuhan epidemic that has been deleted from the NIH’s Sequence Read Archive. I recover the deleted files from the Google Cloud, and reconstruct partial sequences of 13 early epidemic viruses.
Scientists: VT’s Allegation of COVID’s Origins Need Study
On 30 December 2019, the Program for Monitoring Emerging Diseases notified the world about a pneumonia of unknown cause in Wuhan, China (1). Since then, scientists have made remarkable progress in understanding the causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its transmission, pathogenesis, and mitigation by vaccines, therapeutics, and non-pharmaceutical interventions. Yet more investigation is still needed to determine the origin of the pandemic.
Investigate the origins of COVID-19
(0)eLetters eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter. Log In to Submit a Response
Investigate the origins of COVID-19
(0)eLetters eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter. Log In to Submit a Response
Co-dominant neutralizing epitopes make anti-measles immunity resistant to viral evolution
Munoz-Alia and colleagues 1 Muñoz-Alía M.A. Nace R.A. Zhang L. Russell S.J. Serotypic evolution of measles virus is constrained by multiple co-dominant B cell epitopes on its surface glycoproteins. Cell Rep. Med. 2021; 2: 100225 demonstrate that neutralizing antibody immunity to measles resists viral evolutionary escape because it targets numerous distinct viral epitopes. Their work contributes to our understanding of what determines whether a virus can evolve to evade immunity.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jesse
Contact Jesse, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack